Request Free Legal Consultation
Phase III
Phase III Randomized Study of Fentanyl Sublingual Spray for Breakthrough Cancer Pain in Patients Who are Opioid Tolerant
Phase III
Location:
The Woodlands, TX: InSys Therapeutics, Incorporated
Trial Summary:
Primary Objective:
- Determine the efficacy and safety of fentanyl sublingual (SL) spray for the treatment of breakthrough cancer pain in patients on around-the-clock opioids for their persistent cancer pain.
Secondary Objectives:
- Evaluate the safety of fentanyl SL spray in these opioid-tolerant patients.
- Assess the patient’s satisfaction with treatment medication.
Contact Information:
Ramesh Acharya, MD, Protocol chair
Ph: 602-910-2617
For Additional Information, Click Here
THE SOKOLOVE PROMISE